9/28/2018 Milatuzumab - DrugBank
Milatuzumab
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
IDENTIFICATION
Name Milatuzumab
Accession Number DB12943
Type Biotech
Groups
Investigational
Biologic Classification Protein Based Therapies Monoclonal antibody (mAb)
Description
Milatuzumab has been used in trials studying the treatment of Lupus Nephritis, Multiple Myeloma (MM), GVHD (Acute or Chronic), Myelodysplastic Syndrome, and Chronic Lymphocytic Leukemia, among others.
Protein chemical formula https://www.drugbank.ca/drugs/DB12943 1/8 9/28/2018 Milatuzumab - DrugBank
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
Not Available
Categories
Amino Acids, Peptides, and Proteins
Antibodies
Antibodies, Monoclonal
Blood Proteins
Globulins
Immunoglobulins
Immunoproteins
Proteins
Serum Globulins
UNII 2OP4E0GC6V
CAS number
899796-83-9
PHARMACOLOGY
Indication
Not Available https://www.drugbank.ca/drugs/DB12943 2/8 9/28/2018 Milatuzumab - DrugBank
Pharmacodynamics Not Available
Mechanism of action Not Available
Absorption Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination Not Available
Half life Not Available
Clearance Not Available
Toxicity
Not Available
Affected organisms Not Available
Pathways Not Available https://www.drugbank.ca/drugs/DB12943 3/8 9/28/2018 Milatuzumab - DrugBank
Pharmacogenomic Effects/ADRs
Not Available
INTERACTIONS
Drug Interactions
ALL DRUGS APPROVED VET APPROVED NUTRACEUTICAL ILLICIT
WITHDRAWN INVESTIGATIONAL EXPERIMENTAL
Search
DRUG ↑↓ INTERACTION ↑↓ Abciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Milatuzumab.
Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Milatuzumab.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Milatuzumab.
Anthrax immune globulin The therapeutic efficacy of Anthrax immune globulin human can be human decreased when used in combination with Milatuzumab.
Antithymocyte The risk or severity of adverse effects can be increased when immunoglobulin (rabbit) Antithymocyte immunoglobulin (rabbit) is combined with Milatuzumab.
Bacillus calmette-guerin The therapeutic efficacy of Bacillus calmette-guerin substrain substrain connaught live connaught live antigen can be decreased when used in combination antigen with Milatuzumab.
Bacillus calmette-guerin The therapeutic efficacy of Bacillus calmette-guerin substrain tice live substrain tice live antigen antigen can be decreased when used in combination with Milatuzumab.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Milatuzumab.
BCG vaccine The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Milatuzumab.
Belimumab The risk or severity of adverse effects can be increased when Milatuzumab is combined with Belimumab. https://www.drugbank.ca/drugs/DB12943 4/8 9/28/2018 Milatuzumab - DrugBank
Showing 1 to 10 of 47 entries ‹ ›
Food Interactions
Not Available
REFERENCES
General References
Not Available
External Links PubChem Substance
347911409
Wikipedia
Milatuzumab
CLINICAL TRIALS
Clinical Trials
Search
PHASE ↑↓ STATUS ↑↓ PURPOSE ↑↓ CONDITIONS ↑↓ COUNT ↑↓ 1 Active Not Treatment Acute Myeloid or Lymphoblastic Leukemia (AML or 1 Recruiting ALL) / Chronic Chronic myelogenous leukemia / Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia (CLL or SLL) / GVHD (Acute or Chronic) / Multiple Myeloma (MM) / Myelodysplastic Syndrome / Non-Hodgekin Lymphoma (NHL-both Follicular & Diffuse Large Cell)
1, 2 Completed Treatment Chronic Lymphocytic Lymphoma 1
1, 2 Completed Treatment Malignant Lymphomas 1
1, 2 Completed Treatment Multiple Myeloma (MM) / Myeloma, Plasma-Cell / 1 Plasmacytoma https://www.drugbank.ca/drugs/DB12943 5/8 9/28/2018 Milatuzumab - DrugBank
PHASE ↑↓ STATUS ↑↓ PURPOSE ↑↓ CONDITIONS ↑↓ COUNT ↑↓
1, 2 Recruiting Treatment Lupus Erythematosus, Cutaneous / Lupus 1 Erythematosus, Discoid / Lupus Erythematosus, Systemic / Lupus Vasculitis, Central Nervous System / Nephritis, Lupus
1, 2 Unknown Treatment Chronic Lymphocytic Leukaemia (CLL) 1 Status
Showing 1 to 6 of 6 entries ‹ ›
PHARMACOECONOMICS
Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices Not Available
Patents
Not Available
PROPERTIES
State
Not Available
Experimental Properties Not Available
https://www.drugbank.ca/drugs/DB12943 6/8 9/28/2018 Milatuzumab - DrugBank
TAXONOMY
Description Not Available
Kingdom
Organic Compounds
Super Class Organic Acids
Class Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent Peptides
Alternative Parents
Not Available
Substituents Not Available
Molecular Framework Not Available
External Descriptors
Not Available
Drug created on October 20, 2016 19:30 / Updated on August 02, 2018 06:45
About https://www.drugbank.ca/drugs/DB12943 7/8 9/28/2018 Milatuzumab - DrugBank About DrugBank
DrugBank Blog Wishart Research Group Terms of Use
Privacy Policy
Support
FAQ Help Email Support
Commercial Products API Pricing
API Docs Data Licenses Support
This project is supported by the Canadian Institutes of Health Research (award #111062), Alberta Innovates - Health Solutions, and by The Metabolomics Innovation Centre (TMIC), a nationally-funded research and core facility that supports a wide range of cutting-edge metabolomic studies. TMIC is funded by Genome Alberta, Genome British Columbia, and Genome Canada, a not-for-profit organization that is leading Canada's national genomics strategy with funding from the federal government. Maintenance, support, and commercial licensing is provided by OMx Personal Health Analytics, Inc. Designed by Educe Design & Innovation Inc.
https://www.drugbank.ca/drugs/DB12943 8/8